Male hormonal contraception: hope and promise

Lancet Diabetes Endocrinol. 2017 Mar;5(3):214-223. doi: 10.1016/S2213-8587(16)00034-6. Epub 2016 Feb 23.

Abstract

Family planning is a shared responsibility, but available male-directed contraceptive methods are either not easily reversible (vasectomy) or not sufficiently effective (condom). However, roughly 20% of couples using a contraceptive method worldwide, and up to 80% in some countries, still choose a male-directed method. Male hormonal contraception is highly effective, with perfect use failure rates of 0·6% (95% CI 0·3-1·1) if sperm concentrations of less than 1 million per mL are maintained. After cessation of male hormonal contraception, sperm output fully recovers in a predictable manner, resulting in pregnancies and livebirths. Spontaneous miscarriage and fetal malformation rates after recovery of sperm output overlap those in the general population. Short-term adverse events-acne, night sweats, increased weight, and altered mood and libido-are recognised, but are generally mild. Further optimisation of specific androgen-progestin regimens and phase 3 studies of lead combinations are still needed to successfully develop an approved male hormonal contraceptive and to identify long-term side-effects.

Publication types

  • Review
  • Research Support, N.I.H., Extramural

MeSH terms

  • Androgens / therapeutic use
  • Contraception / methods*
  • Contraceptive Agents, Male / therapeutic use*
  • Female
  • Humans
  • Male
  • Pregnancy
  • Pregnancy Outcome
  • Progestins / therapeutic use
  • Risk Factors

Substances

  • Androgens
  • Contraceptive Agents, Male
  • Progestins